Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1978 1
1981 1
1984 1
1985 5
1986 1
1987 1
1988 3
1989 2
1990 6
1993 2
1994 7
1995 5
1996 5
1997 6
1998 6
1999 1
2000 4
2001 10
2002 2
2003 5
2004 5
2005 6
2006 4
2007 11
2008 11
2009 12
2010 9
2011 9
2012 14
2013 15
2014 12
2015 19
2016 11
2017 7
2018 12
2019 15
2020 11
2021 11
2022 10
2023 13
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

267 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Unresectable Kidney Carcinoma"
Page 1
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. Balar AV, et al. Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26. Lancet Oncol. 2017. PMID: 28967485 Clinical Trial.
BACKGROUND: More than half of all patients with advanced urothelial cancer cannot receive standard, first-line cisplatin-based chemotherapy because of renal dysfunction, poor performance status, or other comorbidities. ...Pembrolizumab in the first-line setting is being fu …
BACKGROUND: More than half of all patients with advanced urothelial cancer cannot receive standard, first-line cisplatin-based chemotherapy …
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Sharma P, et al. Lancet Oncol. 2017 Mar;18(3):312-322. doi: 10.1016/S1470-2045(17)30065-7. Epub 2017 Jan 26. Lancet Oncol. 2017. PMID: 28131785 Clinical Trial.
We assessed nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for safety and activity in patients with metastatic or surgically unresectable urothelial carcinoma whose disease progressed or recurred despite previous treatment with at least one …
We assessed nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for safety and activity in patients with metastatic or …
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Powles T, et al. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
We assessed the overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or without tremelimumab (a CTLA-4 inhibitor), as a first-line treatment for metastatic urothelial carcinoma. METHODS: DANUBE is an open-label, randomised, controlled, phas …
We assessed the overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or without tremelimumab (a CTLA-4 inhibitor), …
Sunitinib.
Heng DY, Kollmannsberger C. Heng DY, et al. Recent Results Cancer Res. 2010;184:71-82. doi: 10.1007/978-3-642-01222-8_6. Recent Results Cancer Res. 2010. PMID: 20072832 Review.
These attributes have proven to be efficacious in the treatment of metastatic renal cell carcinoma (RCC) and unresectable gastrointestinal stromal tumors (GIST). ...This chapter will detail the preclinical data leading to the results of the pivotal pha …
These attributes have proven to be efficacious in the treatment of metastatic renal cell carcinoma (RCC) and unresec …
Immunotherapy-based combinations: an update.
Fucà G, de Braud F, Di Nicola M. Fucà G, et al. Curr Opin Oncol. 2018 Sep;30(5):345-351. doi: 10.1097/CCO.0000000000000466. Curr Opin Oncol. 2018. PMID: 29994900 Review.
PURPOSE OF REVIEW: The advent of immunotherapy significantly improved clinical outcomes in cancer patients, although immune checkpoint blockade (ICB) still lack of efficacy in a consistent proportion of treated patients. ...RECENT FINDINGS: First-line combinatorial treatme …
PURPOSE OF REVIEW: The advent of immunotherapy significantly improved clinical outcomes in cancer patients, although immune checkpoin …
Combined use of pembrolizumab and lenvatinib: A review.
Eisinger C, Muluneh B. Eisinger C, et al. J Oncol Pharm Pract. 2023 Sep;29(6):1461-1466. doi: 10.1177/10781552231178461. Epub 2023 May 25. J Oncol Pharm Pract. 2023. PMID: 37231712 Free PMC article. Review.
Data suggests that combination therapy with pembrolizumab and lenvatinib can be used first line for clear cell renal carcinoma in patients with favorable risk or intermediate/poor risk and in endometrial carcinoma as a preferred second-line regimen for …
Data suggests that combination therapy with pembrolizumab and lenvatinib can be used first line for clear cell renal carcin …
Sunitinib.
Deeks ED, Keating GM. Deeks ED, et al. Drugs. 2006;66(17):2255-66; discussion 2267-8. doi: 10.2165/00003495-200666170-00007. Drugs. 2006. PMID: 17137406 Review.
In a phase III, randomised, double-blind, placebo-controlled, multicentre trial in patients with metastatic and/or unresectable GIST following unsuccessful imatinib therapy, the median time to tumour progression and median progression-free survival time were …
In a phase III, randomised, double-blind, placebo-controlled, multicentre trial in patients with metastatic and/or unresect …
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
BACKGROUND: Despite multimodal therapy, 5-year overall survival for locally advanced head and neck squamous cell carcinoma (HNSCC) is about 50%. We assessed the addition of pembrolizumab to concurrent chemoradiotherapy for locally advanced HNSCC. METHODS: In the …
BACKGROUND: Despite multimodal therapy, 5-year overall survival for locally advanced head and neck squamous cell carcinoma (HN …
Lenvatinib-related renal microangiopathy: a case series.
Delsante M, Monroy-Trujillo JM, Carter-Monroe N, Ball DW, Rosenberg AZ. Delsante M, et al. Virchows Arch. 2022 Feb;480(2):467-473. doi: 10.1007/s00428-021-03114-5. Epub 2021 May 6. Virchows Arch. 2022. PMID: 33959820
Lenvatinib is a multiple kinase inhibitor approved by the Food and Drugs Administration (FDA) for the treatment of advanced and radioresistant thyroid carcinomas and, in combination with everolimus, for renal cell carcinoma and unresectable hepatocellu …
Lenvatinib is a multiple kinase inhibitor approved by the Food and Drugs Administration (FDA) for the treatment of advanced and radioresista …
Surgical management of metastatic renal cell carcinoma.
Ball MW. Ball MW. Discov Med. 2017 Jun;23(129):379-387. Discov Med. 2017. PMID: 28877449 Free article. Review.
Despite advances in systemic therapy for metastatic renal cell carcinoma, durable responses remain rare and surgical management remains a mainstay of treatment for many patients with metastatic disease. ...Herein, the evidence for surgical management of both …
Despite advances in systemic therapy for metastatic renal cell carcinoma, durable responses remain rare and surgical ma …
267 results